Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial.

Published

Journal Article

The objective was to examine duloxetine 60-120 mg/day treatment for relapse prevention in adults with generalized anxiety disorder (GAD). Adult patients (N=887; mean age=43.3 years; 61.0% female) with DSM-IV-TR-defined GAD diagnosis were treated with duloxetine for 26 weeks. Patients who completed open-label phase and were treatment responders (>or=50% reduction in Hamilton Anxiety Rating Scale total score to or=2-point increase in illness severity ratings or by discontinuation due to lack of efficacy. During the double-blind phase, placebo-treated patients (N=201) relapsed more frequently (41.8%) than duloxetine-treated patients (13.7%, N=204, P

Full Text

Duke Authors

Cited Authors

  • Davidson, JRT; Wittchen, H-U; Llorca, P-M; Erickson, J; Detke, M; Ball, SG; Russell, JM

Published Date

  • September 2008

Published In

Volume / Issue

  • 18 / 9

Start / End Page

  • 673 - 681

PubMed ID

  • 18559291

Pubmed Central ID

  • 18559291

Electronic International Standard Serial Number (EISSN)

  • 1873-7862

International Standard Serial Number (ISSN)

  • 0924-977X

Digital Object Identifier (DOI)

  • 10.1016/j.euroneuro.2008.05.002

Language

  • eng